Screening Device for Differentiated Primary Cell Models of Airway Epithelia

气道上皮分化原代细胞模型筛选装置

• 批准号: 8515510
• 负责人: Robert G Lowery
• 金额: $ 19.4万
• 依托单位: BELLBROOK LABS, LLC
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8515510
• 关键词: Academia; Air; Animal Testing; Biological Assay; Biological Availability; Biological Process; Biomedical Research; Blood - brain barrier anatomy; Cell Line; Cell model; Cells; Chronic; Chronic Obstructive Airway Disease; Consumption; Cosmetics; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Devices; Disease; Disease model; Drug Transport; Electrophysiology (science); Epithelial; Feasibility Studies; Genetic Engineering; Goals; Gold; Growth; Height; Human; Image; Industry; Inflammatory; Inflammatory Response; Investments; Ion Channel; Kidney Diseases; Liquid substance; Lung; Lung diseases; Marketing; Microscopy; Modeling; Nose; Optics; Oral; Other Genetics; Permeability; Pharmaceutical Preparations; Play; Polycystic Kidney Diseases; Preclinical Drug Evaluation; Price; Proteins; Reagent; Reporter; Research; Resolution; Respiratory Tract Infections; Robotics; Role; Savings; Skin; Skin Cancer; Solutions; System; Techniques; Technology; Testing; Therapeutic; Tissues; Vitelliform macular dystrophy; airway epithelium; airway surface liquid; cost; cytokine; density; design; drug candidate; drug development; drug discovery; evaporation; eye dryness; high throughput screening; human disease; immortalized cell; immunocytochemistry; improved; instrument; interest; meetings; miniaturize; novel; operation; overexpression; programs; prototype; public health relevance; response; screening; success; tool; trafficking

DESCRIPTION (provided by applicant): Approaches to drug screening typically involve dramatic compromises in order to achieve high throughput and hold down costs. Examples include the use of immortalized, heterologous cell lines, and genetic engineering to over-express the target protein and/or incorporate a fluorescent surrogate reporter to display the result. At least partly because such systems often produce responses that are not relevant to the actual human disease state, high throughput screening has not historically delivered a strong return on investment. More representative primary cell models are often available for tissues and diseases, but these models are underutilized in screening because of the lack of technological solutions and high costs. For similar reasons, more relevant assay technologies such as endogenous immunocytochemistry and electrophysiology are not commonly employed in HTS. The goal of this project is to bring the gold standard, organotypic cell model for airway epithelia into true high throughput screening, and enable the use of more informative high content assays including endogenous CFTR trafficking and airway surface liquid height. In addition to applications for cystic fibrosis and COPD, the resultant device will also be valuable for skin models and drug transport studies. The device consists of an array of 96 microchambers in standard microplate format. The microchamber design is small enough to be compatible with 384-well plate densities, so 384 microchambers per plate is readily achievable. The plate includes specialized features for compatibility and ease-of-use with standard liquid handling robotics, and high resolution microscopy. Importantly, the device is simple enough to be produced at a cost consistent with the cost constraints of HTS labs, and confers dramatic savings in primary cell and media consumption. The feasibility study on a small-scale device was successfully completed, indicating that the highly miniaturized approach is compatible with organotypic epithelial airway culture at air-liquid interface. Although not an aim of this proposal this device is designed to be integrated into an electrophysiology instrument designed specifically for this culture system.

描述（由申请人提供）：药物筛选的方法通常涉及巨大的妥协，以实现高通量和降低成本。例子包括使用永生化、异种细胞系和基因工程来过表达目标蛋白和/或结合荧光替代报告细胞来显示结果。至少部分原因是这种系统通常产生的反应与实际的人类疾病状态无关，高通量筛选在历史上并没有带来强大的投资回报。通常有更有代表性的原代细胞模型用于组织和疾病，但由于缺乏技术解决方案和成本高，这些模型在筛选中未得到充分利用。由于类似的原因，内源性免疫细胞化学和电生理等更相关的检测技术在HTS中不常用。该项目的目标是将金标准，气道上皮器官型细胞模型带入真正的高通量筛选，并能够使用更多信息丰富的高含量检测，包括内源性CFTR运输和气道表面液体高度。除了囊性纤维化和慢性阻塞性肺病的应用外，该装置也将对皮肤模型和药物运输研究有价值。该装置由96个标准微孔板格式的微室阵列组成。微室设计足够小，可以与384孔板密度兼容，因此每个板384个微室很容易实现。该板包括专用功能的兼容性和易用性的标准液体处理机器人，和高分辨率显微镜。重要的是，该设备足够简单，生产成本与HTS实验室的成本限制一致，并且大大节省了原代细胞和培养基的消耗。在小型装置上的可行性研究成功完成，表明高度小型化的方法与气液界面的器官型上皮气道培养是兼容的。虽然不是本提案的目的，但该装置被设计成集成到专门为该培养系统设计的电生理仪器中。